We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+3.84%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$306M
AUM Growth
+$45.6M
Cap. Flow
+$57.6M
Cap. Flow %
18.83%
Top 10 Hldgs %
85.78%
Holding
34
New
9
Increased
9
Reduced
4
Closed
8

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$16.5M
2
IMMU
Immunomedics Inc
IMMU
+$12.4M
3
FBRX icon
Forte Biosciences
FBRX
+$11.3M
4
ALDR
Alder Biopharmaceuticals
ALDR
+$10.1M
5
BPMC
Blueprint Medicines
BPMC
+$8.48M

Top Sells

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$5.78M
2
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$5.75M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$4.44M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.17M
5
IRTC icon
iRhythm Holdings
IRTC
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 44.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$102M 33.48%
1,950,477
+353,776
+22% +$16.5M
AKAO
2
DELISTED
Achaogen Inc
AKAO
$27.2M 8.87%
1,250,000
+4,813
+0.4% +$110K
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$24.9M 8.14%
2,177,203
+547,981
+34% +$10.1M
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$23.3M 7.61%
460,000
+199,600
+77% +$8.48M
AIMT
5
DELISTED
Aimmune Therapeutics
AIMT
$18.8M 6.13%
912,001
– –
WVE icon
6
Wave Life Sciences
WVE
$1.13B
$18.7M 6.1%
1,004,100
+327,972
+49% +$7.07M
IMMU
7
DELISTED
Immunomedics Inc
IMMU
$17.1M 5.6%
1,940,850
+1,767,979
+1,023% +$12.4M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$12.1M 3.94%
799,363
+117,441
+17% +$1.78M
FBRX icon
9
Forte Biosciences
FBRX
$1.57B
$9.06M 2.96%
+2,008
New +$11.3M
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
$9.02M 2.95%
112,500
+12,500
+13% +$693K
KYNB
11
Kyntra Bio
KYNB
$29M
$8.07M 2.64%
10,000
+6,481
+184% +$4.51M
VRNA
12
DELISTED
Verona Pharma
VRNA
$7.15M 2.34%
+613,601
New +$8.13M
BLCM
13
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.29M 1.73%
45,273
-46,527
-51% -$5.78M
DERM
14
DELISTED
Dermira, Inc.
DERM
$5.13M 1.68%
176,211
– –
PACB icon
15
Pacific Biosciences
PACB
$435M
$4.45M 1.45%
+1,250,000
New +$5.04M
ARGX icon
16
argenx
ARGX
$54.9B
$3.74M 1.22%
+176,500
New +$3.67M
NSTG
17
DELISTED
NanoString Technologies, Inc.
NSTG
$2.96M 0.97%
178,681
-139,905
-44% -$2.47M
SGMO
18
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.35M 0.44%
+154,000
New +$988K
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.16M 0.38%
+738,896
New +$1.43M
OREX
20
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.1M 0.36%
380,530
– –
LRMR icon
21
Larimar Therapeutics
LRMR
$392M
$822K 0.27%
19,508
-11,398
-37% -$583K
BHVN
22
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$750K 0.25%
+30,000
New +$691K
ASND icon
23
Ascendis Pharma A/S
ASND
$16.3B
$622K 0.2%
22,400
-77,600
-78% -$2.05M
XLRN
24
DELISTED
Acceleron Pharma
XLRN
$604K 0.2%
19,886
– –
ARDX icon
25
Ardelyx
ARDX
$1.26B
$191K 0.06%
+37,500
New +$318K
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q2 2017 Portfolio in Review

As of Q2 2017, Foresite Capital Management III held 34 positions worth $306M, up 17% from $261M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Foresite Capital Management III deployed $57.6M of net new capital in Q2 2017, opening 9 new positions and adding to 9 existing holdings. Its largest new stake was Forte Biosciences: 2,008 shares worth $9.06M.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 50% a quarter earlier.

On the sell side, the largest reduction was Bellicum Pharmaceuticals, Inc., an estimated $5.78M trimmed.

  • Foresite Capital Management III's largest Q2 2017 buy was Forte Biosciences: 2,008 shares worth $9.06M.
  • Foresite Capital Management III added most to Aerie Pharmaceuticals in Q2 2017, an estimated $16.5M increase.
  • Foresite Capital Management III's biggest Q2 2017 reduction was Bellicum Pharmaceuticals, Inc., cutting an estimated $5.78M.
  • Foresite Capital Management III fully exited Momenta Pharmaceuticals, Inc. in Q2 2017, selling an estimated $5.75M.
  • Foresite Capital Management III's ten largest holdings make up 86% of its $306M portfolio in Q2 2017.
  • Foresite Capital Management III opened 9 new positions and closed 8 in Q2 2017.
  • Foresite Capital Management III's portfolio value rose 17% quarter-over-quarter to $306M.

Based on Foresite Capital Management III's 13F filing for Q2 2017, filed 14 Aug 2017.